Published

Innovent Biologics to Present Key Cancer Drug Data at ESMO Asia, Including Promising Pancreatic Treatment

Summary by stocktitan.net
Innovent Biologics unveils clinical data for multiple cancer treatments at ESMO Asia 2024, featuring breakthrough results for pancreatic cancer drug IBI343 and studies across major cancer types.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics